Table 3.
Current status of CTs of NC and SC-based therapies on COVID-19 infection [80]
| Sr. no. | Title | Trial Identifier | Phase | Study design | Intervention/Treatment | Responsible party |
|---|---|---|---|---|---|---|
| 1 | Mesenchymal SC therapy for SARS-CoV-2-related acute respiratory distress syndrome | NCT04366063 | III | Interventional (60 participants), Randomized trial | 2 doses of mesenchymal SC (100 × 10)6 at day 0 and 2, intravenously plus 2 doses of extracellular vesicles at day 4 and 6 with conventional treatment. | Royan Institute, Iran |
| 2 | Study evaluating the safety and efficacy of autologous non-hematopoietic peripheral blood SC in COVID-19 | NCT04473170 | II | Interventional (146 participants), Randomized study | Autologous non-hematopoietic peripheral blood SC by jet nebulization technique | Abu Dhabi Stem Cells Center, UAE |
| 3 | Corona virus treatment with umbilical cord-derived mesenchymal SC | NCT04288102 | II | Interventional (100 participants), Randomized study | 3 doses of umbilical cord- mesenchymal SC administered intravenously at day 0, 3 and 6 | Fu-Sheng Wang, Beijing 302 Hospital, China |
| 4 | Mesenchymal SC infusion for COVID-19 infection | NCT04444271 | II | Interventional (20 participants), Randomized trial | Mesenchymal SC of dose (2 × 10)6 cells/kg on day 1 and 7 | Dr. Zaineb Akram, National Institute of Blood and Marrow Transplant (NIBMT), Pakistan |
| 5 | Mesenchymal SC for acute respiratory distress syndrome due to COVID-19 | NCT04416139 | II | Interventional (10 participants), non-randomized trial | Mesenchymal SC intravenous infusion | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran Mexico City, Mexico |
| 6 | Bone marrow-derived mesenchymal SC treatment for severe patients with corona virus disease 2019 | NCT04346368 | II | Interventional (20 participants), Randomized study | Bone marrow-derived mesenchymal SC | Guangzhou Institute of Respiratory Health, China |
| 7 | Clinical research of human mesenchymal SC in the treatment of COVID-19 pneumonia | NCT04339660 | II | Interventional (30 participants), Randomized trial | Umbilical cord- mesenchymal SC | Puren Hospital Affiliated to Wuhan University of Science and Technology Wuhan, China |
| 8 | Mesenchymal SCs for the treatment of COVID-19 | NCT04573270 | I | Interventional (40 participants), Randomized study | PrimePro (Umbilical cord SC) intravenous injection | Thomas Advanced Medical LLC, California, US |
| 9 | A pilot clinical study on inhalation of mesenchymal SC exosomes treating severe novel corona virus pneumonia | NCT04276987 | I | Interventional (24 participants) | Mesenchymal SC exosomes | Ruijin Hospital, China |
| 10 | Cord blood-derived mesenchymal SC for the treatment of COVID-19 related acute respiratory distress syndrome | NCT04565665 | I | Interventional (70 participants), Randomized trial | Infusion of cord blood mesenchymal SC | M.D. Anderson Cancer Center, US |
| 11 | Clinical use of SC for the treatment of COVID-19 | NCT04392778 | I | Interventional (30 participants), Randomized | Mesenchymal SC administered intravenously (3 Mn cells/kg) on day 0, 3 and 6 | Istinye University Istanbul, Turkey |
| 12 | An exploratory study of ADR-001 in patients with severe pneumonia caused by SARS-CoV-2 infection | NCT04522986 | I | Interventional (6 participants) | Mesenchymal SC administered weekly (4 times) intravenously (1 × 10)8 cells | Osaka University Hospital Suita, Japan |
| 13 | Treatment of COVID-19 patients using Wharton’s Jelly-mesenchymal SC | NCT04313322 | I | Interventional (5 participants) | 3 doses of Wharton’s Jelly-mesenchymal SC received intravenously | Adeeb Al Zoubi, Stem Cells Arabia, Jordan |
| 14 | Effectiveness of a novel respirator with chitosan nanoparticles | NCT04490200 | – | Interventional (1000 participants), Randomized trial | VESTA respirator compared to N95 respirator | University of Brasilia, Brazil |
| 15 | Efficacy and safety of methotrexate-loaded nanoparticles to treat severe COVID-19 patients | NCT04352465 | II | Interventional (42 participants), non-randomized trial | 3 doses of methotrexate nanoparticles administered once a week | Azidus Brasil, Brazil |